**Supplemental Table 1**. Baseline characteristics of the study sample, by treatment regimen assigned.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
| **Variable** | **STR-Atripla®** | **MTR-SC** | **MTR Other** | **P Value** | **Overall** |
|  | **n=759** | **n=483** | **n=1531** |  | **n=2772** |
| Age, median (IQR) | 37 (31;43) | 37 (31;44) | 37 (30;44) | 0.6572 2 | 37 (31;44) |
| Gender, male (%) | 673 (89) | 407 (84) | 1233 (81) | < 0.0001 2 | 2313 (83) |
| Risk group |  |  |  | <0.0001 2 |  |
| IVDU | 41 (6) | 34 (7) | 143 (10) |  | 218 (8) |
| MSM | 516 (70) | 263 (55) | 862 (58) |  | 1641 (60) |
| Heterosexual | 158 (21) | 164 (34) | 453 (30) |  | 775 (29) |
| Other | 24 (3) | 16 (3) | 40 (2) |  | 80 (3) |
| Median baseline CD4 count, cells/mm3 (IQR) | 328 (225;446) | 274 (175;381) | 300 (179;415) | <0.0001 3 | 305 (189;416) |
| CD4 < 200 cells/mm3 (n, %) | 153 (20) | 151 (31) | 445 (29) | <0.0001 2 | 749 (27) |
| Median HIV-1 RNA, log10 copies/mL (IQR) | 4.6 (3.8;5.1) | 4.4 (3.2;5.1) | 4.4 (3.6;5.1) | 0.0477 3 | 4.5 (3.6;5.1) |
| HIV-1 RNA ≥100.000 copies/mL (n,%) | 239 (31) | 152 (31) | 450 (29) | 0.4926 | 841 (30) |
| Positive HCV antibodies (n,%) | 83 (11) | 75 (16) | 245 (16) | 0.0041 | 403 (15) |

STR: Single-tablet regimen; MTR: Multi-tablet regimen; MTR-SC: Multi-tablet regimen with same components as Atripla®; MTR Other: multi-tablet regimen with other drugs different than the components of Atripla®; IVDU: intravenous drug users; MSM: men having sex with men; HCV hepatitis C virus; 1 Wilcoxon Rank Sum test. 2 Chi-squared test. 3Kruskal-Wallis test.

**Supplemental Table 2.** Antiretroviral regimens most commonly prescribed in the MTR-Other arm (n=1531).

|  |  |  |
| --- | --- | --- |
| **Antiretroviral regimen** | **N** | **%** |
| Darunavir/ritonavir + emtricitabine/tenofovir DF | 337 | 22 |
| Atazanavir/ritonavir + emtricitabine/tenofovir DF | 262 | 17 |
| Lopinavir/ritonavir + emtricitabine/tenofovir DF | 224 | 15 |
| Nevirapine + emtricitabine/tenofovir DF | 136 | 9 |
| Raltegravir + emtricitabine/tenofovir DF | 81 | 5 |
| Darunavir/ritonavir + lamivudine/abacavir | 52 | 3 |
| Nevirapine + lamivudine/abacavir | 48 | 3 |
| Lopinavir/ritonavir + lamivudine/ zidovudine | 48 | 3 |
| Lopinavir/ritonavir + lamivudine/ abacavir | 42 | 3 |
| Darunavir/ritonavir + raltegravir | 39 | 3 |
| Atazanavir/ritonavir + lamivudine/abacavir | 38 | 2 |
| Rilpivirine/emtricitabine/tenofovir DF | 21 | 1 |
| Fosamprenavir/ritonavir + emtricitabine/tenofovir DF | 19 | 1 |
| Efavirenz + lamivudine/abacavir | 17 | 1 |
| Raltegravir + lamivudine/abacavir | 16 | 1 |
| Lopinavir/ritonavir + raltegravir | 11 | 1 |
| Dolutegravir + lamivudine/abacavir | 11 | 1 |
| Fosamprenavir/ritonavir + lamivudine/abacavir | 10 | 1 |
| Dolutegravir + emtricitabine/tenofovir DF | 9 | 1 |
| Raltegravir + Maraviroc + emtricitabine/tenofovir DF | 9 | 1 |
| Etravirine + emtricitabine/tenofovir DF | 7 | 0 |
| Lopinavir/ritonavir + lamivudine | 7 | 0 |
| Other | 87 | 6 |

DF: Disoproxil fumarate.

**Supplemental Table 3.** Cost, effectiveness, cost/effectiveness (efficiency), and relative efficiency at 48 weeks of initiating treatment with each regimen of antiretroviral treatment (cost values in €).

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | Base-case scenario | | | | | Most favourable scenario | | | Least favourable scenario | | |
|  | Cost of ART | Cost of initiating ART | Effectiveness | CE | Relative CE | Effectiveness | CE | Relative CE | Effectiveness | CE | Relative CE |
| STR-Atripla® | 7.370 | 9419 | 0.76 | 12406 | 1 | 0.80 | 13127 | 1 | 0.72 | 11761 | 1 |
| MTR-SC | 6736 | 8202 | 0.74 | 11034 | 0.89 | 0.86 | 12979 | 0.99 | 0.63 | 9595 | 0.82 |
| MTR Other | 8350 | 11466 | 0.62 | 18353 | 1.48 | 0.71 | 21072 | 1.61 | 0.54 | 16256 | 1.38 |

ART: antiretroviral treatment; STR: single tablet regimen; MTR: multiple table regimen; SC: same components; Other: other components; CE:cost/effectiveness or cost per responder at 48 weeks of efficiency.

**Supplemental Figure 1.** Kaplan-Meier survival estimates of the proportion of subjects with treatment success (efficiency) stratified by treatment group: ATR-Atripla®, MTR-SC and MTR-Other

****